Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
4(100.0%)
4Total
Phase 1(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05708950Phase 1Unknown

A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)

Role: lead

NCT03993704Phase 1Completed

Multiple Ascending Oral Dose 14-Day Trial of LHF-535 in Healthy Participants

Role: lead

NCT02446340Phase 1Completed

Multiple Ascending Dose Safety Study of ShK-186 (Dalazatide) in Healthy Volunteers

Role: lead

NCT02435342Phase 1Completed

A 4 Week Study of the Safety, Tolerability, and Pharmacodynamics of ShK-186 (Dalazatide) in Active Plaque Psoriasis

Role: lead

All 4 trials loaded